NCT02162420 is a NA clinical trial of Alemtuzumab in Dyskeratosis Congenita, sponsored by Masonic Cancer Center, University of Minnesota.

Who is sponsoring NCT02162420?

NCT02162420 is sponsored by Masonic Cancer Center, University of Minnesota.

What drugs are being tested in NCT02162420?

Interventions in NCT02162420: Alemtuzumab, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem Cell Transplant, Anti-thymocyte globulin.

What condition does NCT02162420 study?

NCT02162420 studies Dyskeratosis Congenita, Aplastic Anemia.

Is NCT02162420 still recruiting?

NCT02162420 is currently completed. Last updated 8 May 2025.

Are results published for NCT02162420?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-05-08 · How we verify

NCT02162420

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

Completed NA Results posted Last updated 8 May 2025

What this trial tests

NA trial testing Alemtuzumab in Dyskeratosis Congenita in 61 participants. Completed in 11 March 2025.

Timeline

10 January 2015

Primary endpoint
8 August 2024

11 March 2025

Quick facts

Lead sponsor	Masonic Cancer Center, University of Minnesota
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	61
Start date	10 January 2015
Primary completion	8 August 2024
Estimated completion	11 March 2025
Sites	1 location across United States

Drugs / interventions tested

Alemtuzumab (ALEMTUZUMAB) — full drug profile →
Fludarabine (FLUDARABINE) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Total Body Irradiation
Stem Cell Transplant — full drug profile →
Anti-thymocyte globulin

Conditions studied

Dyskeratosis Congenita — all drugs for Dyskeratosis Congenita →
Aplastic Anemia — all drugs for Aplastic Anemia →

Sponsor

Masonic Cancer Center, University of Minnesota

Who can join

Adults 0 to 70, any sex, with Dyskeratosis Congenita or Aplastic Anemia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Incidence of Neutrophil Engraftment Primary · Day 42

Incidence of neutrophil engraftment by day 42.

Group	Value	95% CI
Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor	100	0 – 100
Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor	100	0 – 100
Arm C: Severe Aplastic Anemia, Matched Related Donor	96	82 – 100
Arm E: Severe Aplastic Anemia, PTCy Platform	100	0 – 100

Incidence of Platelet Engraftment Primary · 1 year

Incidence of platelet engraftment at 1 year

Group	Value	95% CI
Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor	100	0 – 100
Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor	100	0 – 100
Arm C: Severe Aplastic Anemia, Matched Related Donor	96	82 – 100
Arm E: Severe Aplastic Anemia, Haploidentical Donor	100	0 – 100

Incidence of Regimen Related Mortality Secondary · Day 100

Incidence of regimen related mortality by day 100.

Group	Value	95% CI
Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor	0	0 – 0
Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor	6	1 – 33
Arm C: Severe Aplastic Anemia, Matched Related Donor	6	1 – 33
Arm E: Severe Aplastic Anemia, PTCy Platform	0	0 – 0

Incidence of Acute Graft-versus-host Disease Secondary · Day 100

Incidence of acute graft-versus-host disease by day 100.

Group	Value	95% CI
Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor	0	0 – 0
Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor	11	0 – 25
Arm C: Severe Aplastic Anemia, Matched Related Donor	9	0 – 21
Arm E: Severe Aplastic Anemia, PTCy Platform	0	0 – 0

Incidence of Chronic Graft-versus-host Disease Secondary · 6 Months

Incidence of chronic graft-versus-host disease by 6 months

Group	Value	95% CI
Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor	0	0 – 0
Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor	6	0 – 16
Arm C: Severe Aplastic Anemia, Matched Related Donor	0	0 – 0
Arm E: Severe Aplastic Anemia, PTCy Platform	0	0 – 0

Incidence of Chronic Graft-versus-host Disease Secondary · 1 Year

Incidence of chronic graft-versus-host disease by 1 year

Group	Value	95% CI
Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor	0	0 – 0
Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor	6	0 – 16
Arm C: Severe Aplastic Anemia, Matched Related Donor	0	0 – 0
Arm E: Severe Aplastic Anemia, PTCy Platform	0	0 – 0

Incidence of Secondary Malignancies Secondary · 1 Year

Incidence of secondary malingancies

Group	Value	95% CI
Arm A: Dyskeratosis Congenita, Non-Haploidentical Donor	0	0 – 0
Arm B: Severe Aplastic Anemia, Non-Matched Related, Non-Haploidentical Donor	0	0 – 0
Arm C: Severe Aplastic Anemia, Matched Related Donor	0	0 – 0
Arm E: Severe Aplastic Anemia, PTCy Platform	0	0 – 0

Sponsor's own description

Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell transplant using related or unrelated donor in persons 0-70 years of age diagnosed with dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized by a requirement for red blood cell and platelet transfusions. Three different preparative regimens are included based on disease and donor type.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Alemtuzumab

Trials testing the same drug.

NCT06959771 — Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study · Phase 1, PHASE2 · recruiting
NCT06872333 — Allo HSCT for High Risk Hemoglobinopathies · Phase 2 · recruiting
NCT05501756 — Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation · Phase 2 · recruiting
NCT05384756 — TMLI and Alemtuzumab for Treatment of Sickle Cell Disease · Phase 1 · active not recruiting
NCT06310343 — ADAs to Alemtuzumab · completed

Other recruiting trials for Dyskeratosis Congenita

Currently open trials in the same condition.

NCT04232085 — Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failu · Phase 2 · recruiting
NCT03579875 — Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders · Phase 2 · recruiting
NCT03050268 — Familial Investigations of Childhood Cancer Predisposition · recruiting
NCT00027274 — Cancer in Inherited Bone Marrow Failure Syndromes · recruiting

Other Masonic Cancer Center, University of Minnesota trials

Trials by the same sponsor.

NCT06772090 — Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies · NA · not yet recruiting
NCT06584929 — Rural Smoking Cessation · NA · not yet recruiting
NCT07153016 — LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorect · NA · recruiting
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
NCT07070726 — UNTOLD Ovarian Cancer Unmet Needs Survey · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02162420 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota
Last refreshed: 8 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02162420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing